Perspectives and challenges of interferon-free therapy for chronic hepatitis C

JOURNAL OF HEPATOLOGY

卷:58

Review

Lange, Christian M.¹  Zeuzem, Stefan¹ 

[1] Klinikum JW Goethe Univ Frankfurt Main, Med Klin 1, D-60590 Frankfurt, Germany

关键词: Hepatitis C virus;    Antiviral therapy;    Directly acting antiviral agent;    All-oral therapy;    Null responder;   

DOI  :  10.1016/j.jhep.2012.10.019

来源: Elsevier

【 摘 要 】

Recent data have clearly shown that a sustained virologic response can be achieved in different HCV infected patient populations with various interferon-free treatment regimens. Despite the successful implementation of telaprevir- and boceprevir-based triple therapies, all-oral regimens will certainly become a first choice for a number of HCV-infected patients in the very near future, as triple therapy approaches are burdened with significant side-effects and limited success in patients with advanced liver fibrosis and prior null-response to pegylated interferon-CL (pegIFN-alpha)/ribavirin therapy. However, available data from phase I and II clinical trials evaluating interferon-free regimens have not yet revealed a clearly outstanding all-oral combination, and numerous challenges remain to be addressed by intensive ongoing and future research. In particular, thus far evaluated all-oral regimens did not cure a satisfactory percentage of patients with unfavorable baseline characteristics, namely patients infected with HCV genotype 1a, previous null-response to pegIFN-alpha/ribavirin, or liver cirrhosis. In this review, we summarize available data of interferon-free regimens for the treatment of chronic hepatitis C and assess implications for perspectives and challenges in the further development of all-oral therapies. (C) 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

【 授权许可】

Free